{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:44:17Z","timestamp":1768423457410,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00347-025-02287-7","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T11:39:29Z","timestamp":1754048369000},"page":"48-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Okul\u00e4re Nebenwirkungen von\u00a0Pembrolizumab","Ocular side effects of pembrolizumab"],"prefix":"10.1007","volume":"123","author":[{"given":"Maximilian","family":"Friedrich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Bagautdinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timur Mert","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Aristide","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Khoramnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd Uwe","family":"Auffarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeck-Soo","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2287_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0000000000000154","volume":"40","author":"M Bricout","year":"2017","unstructured":"Bricout\u00a0M, Petre\u00a0A, Amini-Adle\u00a0M et\u00a0al (2017) Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma. J\u00a0Immunother 40:77\u201382","journal-title":"J Immunother"},{"key":"2287_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/ICB.0000000000000999","volume":"16","author":"EW De Vries","year":"2022","unstructured":"De Vries\u00a0EW, Schauwvlieghe\u00a0AS, Haanen\u00a0JB et\u00a0al (2022) Bilateral Serous Retinal Detachment And Uveitis Associated With Pembrolizumab Treatment In Metastatic Melanoma. Retin Cases Brief Rep 16:430\u2013434","journal-title":"Retin Cases Brief Rep"},{"key":"2287_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09273948.2020.1781902","volume":"29","author":"ER Dow","year":"2021","unstructured":"Dow\u00a0ER, Yung\u00a0M, Tsui\u00a0E (2021) Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes. Ocul Immunol Inflamm 29:203\u2013211","journal-title":"Ocul Immunol Inflamm"},{"key":"2287_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10633-020-09800-0","volume":"142","author":"H Enomoto","year":"2021","unstructured":"Enomoto\u00a0H, Kato\u00a0K, Sugawara\u00a0A et\u00a0al (2021) Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment. Doc Ophthalmol 142:353\u2013360","journal-title":"Doc Ophthalmol"},{"key":"2287_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","volume":"105","author":"BH Fortes","year":"2021","unstructured":"Fortes\u00a0BH, Liou\u00a0H, Dalvin\u00a0LA (2021) Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol 105:1263\u20131271","journal-title":"Br J Ophthalmol"},{"key":"2287_CR6","doi-asserted-by":"publisher","first-page":"e00545","DOI":"10.1002\/rcr2.545","volume":"8","author":"Y Kurono","year":"2020","unstructured":"Kurono\u00a0Y, Takeda\u00a0T, Kunimatsu\u00a0Y et\u00a0al (2020) Vogt-Koyanagi-Harada disease during chemoimmunotherapy for non-small cell lung cancer. Respirol Case Rep 8:e545","journal-title":"Respirol Case Rep"},{"key":"2287_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12886-021-02011-4","volume":"21","author":"I Lambert","year":"2021","unstructured":"Lambert\u00a0I, Fasolino\u00a0G, Awada\u00a0G et\u00a0al (2021) Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a\u00a0case report. BMC Ophthalmol 21:250","journal-title":"BMC Ophthalmol"},{"key":"2287_CR8","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/2326-6066.CIR-22-0362","volume":"10","author":"R Reschke","year":"2022","unstructured":"Reschke\u00a0R, Shapiro\u00a0JW, Yu\u00a0J et\u00a0al (2022) Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1\/Tc1 Cytokines. Cancer Immunol Res 10:1167\u20131174","journal-title":"Cancer Immunol Res"},{"key":"2287_CR9","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.jtho.2018.04.026","volume":"13","author":"T Tamura","year":"2018","unstructured":"Tamura\u00a0T, Akimoto\u00a0E, Matsumoto\u00a0C et\u00a0al (2018) Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a\u00a0Patient with Non-Small Cell Lung Cancer. J\u00a0Thorac Oncol 13:1606\u20131607","journal-title":"J Thorac Oncol"},{"key":"2287_CR10","doi-asserted-by":"crossref","unstructured":"Young L, Finnigan S, Streicher H et\u00a0al (2021) Ocular adverse events in PD\u20111 and PD-L1 inhibitors. J\u00a0Immunother Cancer 9:","DOI":"10.1136\/jitc-2020-002119"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-025-02287-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:46:17Z","timestamp":1768391177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-025-02287-7"}},"subtitle":["Bilaterale zentrale ser\u00f6se Netzhautabhebung und Papillitis","Bilateral central serous retinal detachment and papillitis"],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2287"],"URL":"https:\/\/doi.org\/10.1007\/s00347-025-02287-7","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Friedrich, D.\u00a0Bagautdinov, T.M.\u00a0Yildirim, V.A.\u00a0Augustin, R.\u00a0Khoramnia, G.U.\u00a0Auffarth und H.-S.\u00a0Son geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}